Bentley Systems Announces Seequent’s Acquisition of Imago
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that its Seequent business unit has acquired Imago Inc, a developer of cloud-based software for the capture and management of geoscientific imagery. The acquisition will expand Seequent’s technology solutions portfolio while boosting cloud capabilities to help geoscientists and engineers solve earth, environment, and energy challenges.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210803006032/en/
Imago establishes a consistent process for capturing high-quality images, which integrate with existing workflows and allow the application of machine learning. Imago instantly displays machine learning insights together with images during interpretation and modeling. Imago’s on-screen masking and classification tools export data to train models. The Imago Cloud library of geology images provides rich information that supports user interpretation and modeling work. (Photo: Business Wire)
Imago’s cloud-based platform enables the capture, cataloguing, and review of drilling core and chip images from any source, to support every aspect of the geological process from exploration to grade control. Continued development of Imago’s machine learning will lead to a step function in the interpretation of geological data.
Mining companies around the world apply Imago’s solution in conjunction with geology data management and modeling tools to enable teams to make more confident, profitable decisions using instantly available, high-quality images. Seequent already integrates its Leapfrog, Oasis montaj, Target, and Minalytix MX Deposit with Imago’s solution, making it easy for geologists, engineers, and other stakeholders to extract knowledge and learn from geoscientific imagery. The goal is to unlock significant potential for mining and other industries, transforming image data into meaningful insights for geological activities.
Graham Grant, chief executive officer of Seequent, said, “It’s an exciting step to welcome the Imago team on board to help advance Seequent’s progression into the cloud. We’re continually exploring ways to provide new technologies and solutions to solve workflow challenges, improve operational efficiency, and deliver greater value for our users who are working to solve some of the world’s major civil, environmental, and energy challenges. This acquisition demonstrates Seequent’s continued growth and our commitment to make a positive contribution to the industries we serve globally.”
Imago’s co-founder Federico Arboleda said, “As a small team in Phoenix and Perth, we’re excited to join forces with Seequent, as this will now allow us to substantially scale Imago’s solutions in mining and other markets. We founded Imago to help mining companies manage the high volume and size of geological images and unlock the great value in this geoscience imagery. Image data is an increasingly important source of data across the geosciences—and can come from potentially any source, including core photos, hyperspectral, aerial photos, drones, and handheld devices. It will become even more important to transform image data into knowledge as automation needs increase.”
For more information, please visit https://www.imago.live/.
Caption: Imago establishes a consistent process for capturing high-quality images, which integrate with existing workflows and allow the application of machine learning. Imago instantly displays machine learning insights together with images during interpretation and modeling. Imago’s on-screen masking and classification tools export data to train models. The Imago Cloud library of geology images provides rich information that supports user interpretation and modeling work.
Caption: Core boxes displayed in Imago’s platform (right) and in Leapfrog Geo (left). The geologist clicks the drill hole trace to display the corresponding core photos in Imago, as a drill hole, at the correct path. The geologist is able to continuously validate the logs and assays using the original images of the rock material.
Caption: Imago assists companies to deploy processes that improve core image capture.
##
About Seequent
Seequent, a Bentley company, is a world leader in the development of powerful geoscience analysis, modeling, and collaborative technologies for understanding geoscience and engineering design solutions. Our solutions enable people to analyze complex data, manage risk, and ultimately make better decisions about earth, environment, and energy challenges.
Seequent software is used on large-scale projects globally, including road and rail tunnel construction, groundwater detection and management, geothermal exploration, subsea infrastructure mapping, resource evaluation, and subterranean storage of spent nuclear fuel.
Seequent’s global footprint includes its Christchurch-based HQ and R&D centers in Christchurch and Canada with a network of offices across Asia/Pacific, Africa, South America, North America, and Europe, servicing organizations with leading subsurface solutions in over 100 countries. For more information, please visit www.seequent.com or follow Seequent on LinkedIn or Twitter.
About Bentley Systems
Bentley Systems (Nasdaq: BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, and industrial facilities. Our offerings include MicroStation-based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,000 colleagues and generates annual revenues of more than $800 million in 172 countries.
www.bentley.com
© 2021 Bentley Systems, Incorporated. Bentley, the Bentley logo, AssetWise, Imago Inc, iTwin, Leapfrog, MicroStation, Oasis montaj, ProjectWise, Seequent, the Seequent logo, and Target are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210803006032/en/
Contact information
Christine Byrne
+1 203 805 0432
Christine.Byrne@bentley.com
Follow us on Twitter:
@BentleySystems
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currently conducting a global, multi-center Phase 1 clinical trial (NCT06427941) to explore the safety and anti-tumor activity of BGB-B2033, both alone and in combination with PD-1 inhibitor TEVIMBRA® (tisle
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 11:53:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom